Universität zu Köln

Kutsch, Nadine, Fink, Anna Maria and Fischer, Kirsten (2022). Management of front line chronic lymphocytic leukemia. Am. J. Hematol., 97. S. S3 - 8. HOBOKEN: WILEY. ISSN 1096-8652

Full text not available from this repository.

Abstract

Treatment options with targeted agents have changed the treatment landscape of CLL profoundly. Besides chemoimmunotherapy, treatment regimen approved for frontline therapy include continuous treatment with BTK inhibitors like ibrutinib and acalabrutinib or fixed-duration regimen like venetoclax-obinutuzumab with the approval of venetoclax-ibrutinib to be awaited. Although these agents have usually manageable side effects, toxicities might limit choices for the individual patient. We here discuss latest trial data and propose a treatment algorithm for frontline treatment of CLL according to fitness and relevant genetic risk factors like IGHV mutational status and TP53 aberrations.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Kutsch, Nadine UNSPECIFIED UNSPECIFIED UNSPECIFIED Fink, Anna Maria UNSPECIFIED UNSPECIFIED UNSPECIFIED Fischer, Kirsten UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-661475
DOI:	10.1002/ajh.26677
Journal or Publication Title:	Am. J. Hematol.
Volume:	97
Page Range:	S. S3 - 8
Date:	2022
Publisher:	WILEY
Place of Publication:	HOBOKEN
ISSN:	1096-8652
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PREVIOUSLY UNTREATED PATIENTS; ATRIAL-FIBRILLATION; CELL TRANSPLANTATION; TP53 MUTATIONS; ADVERSE EVENTS; FOLLOW-UP; CLL; IBRUTINIB; OBINUTUZUMAB; VENETOCLAX Multiple languages Hematology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/66147